Frazier Life Sciences Management, L.P. An2 Therapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q1 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,388,889 shares of ANTX stock, worth $2.92 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
1,388,889
Previous 1,388,889
-0.0%
Holding current value
$2.92 Million
Previous $28.5 Million
84.14%
% of portfolio
0.24%
Previous 1.75%
Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
55Shares Held
13.2MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$3.27 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.27 Million0.53% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.6 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.56 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.15MShares$2.42 Million0.14% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $40.7M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...